294 related articles for article (PubMed ID: 18483367)
21. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
22. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.
De Placido S; De Laurentiis M; Carlomagno C; Gallo C; Perrone F; Pepe S; Ruggiero A; Marinelli A; Pagliarulo C; Panico L; Pettinato G; Petrella G; Bianco AR
Clin Cancer Res; 2003 Mar; 9(3):1039-46. PubMed ID: 12631604
[TBL] [Abstract][Full Text] [Related]
23. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.
Scartozzi M; Bearzi I; Berardi R; Mandolesi A; Fabris G; Cascinu S
J Clin Oncol; 2004 Dec; 22(23):4772-8. PubMed ID: 15570078
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases.
Furukawa M; Raffeld M; Mateo C; Sakamoto A; Moody TW; Ito T; Venzon DJ; Serrano J; Jensen RT
Clin Cancer Res; 2005 May; 11(9):3233-42. PubMed ID: 15867218
[TBL] [Abstract][Full Text] [Related]
26. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.
Nogi H; Kobayashi T; Suzuki M; Tabei I; Kawase K; Toriumi Y; Fukushima H; Uchida K
Oncol Rep; 2009 Feb; 21(2):413-7. PubMed ID: 19148516
[TBL] [Abstract][Full Text] [Related]
27. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer.
Lu L; Katsaros D; Wiley A; Rigault de la Longrais IA; Risch HA; Puopolo M; Yu H
Clin Cancer Res; 2006 Feb; 12(4):1208-14. PubMed ID: 16489075
[TBL] [Abstract][Full Text] [Related]
28. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
Shariat SF; Bensalah K; Karam JA; Roehrborn CG; Gallina A; Lotan Y; Slawin KM; Karakiewicz PI
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5377-84. PubMed ID: 17875766
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
Law JH; Habibi G; Hu K; Masoudi H; Wang MY; Stratford AL; Park E; Gee JM; Finlay P; Jones HE; Nicholson RI; Carboni J; Gottardis M; Pollak M; Dunn SE
Cancer Res; 2008 Dec; 68(24):10238-46. PubMed ID: 19074892
[TBL] [Abstract][Full Text] [Related]
30. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
31. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis.
Lee CM; Lee RJ; Hammond E; Tsodikov A; Dodson M; Zempolich K; Gaffney DK
Gynecol Oncol; 2004 Apr; 93(1):209-14. PubMed ID: 15047238
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components.
Sarkaria IS; Zakowski MF; Pham D; Hezel M; Ebright MI; Chuai S; Venkatraman ES; Kris MG; Rusch VW; Singh B
Ann Thorac Surg; 2008 Jan; 85(1):216-23. PubMed ID: 18154814
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
Weinberger PM; Yu Z; Kowalski D; Joe J; Manger P; Psyrri A; Sasaki CT
Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):707-11. PubMed ID: 16103303
[TBL] [Abstract][Full Text] [Related]
34. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer.
Yamashita H; Murakami N; Asari T; Okuma K; Ohtomo K; Nakagawa K
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1165-72. PubMed ID: 19101092
[TBL] [Abstract][Full Text] [Related]
35. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
[TBL] [Abstract][Full Text] [Related]
36. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma.
Lee EY; Cibull ML; Strodel WE; Haley JV
Arch Pathol Lab Med; 1994 Mar; 118(3):235-9. PubMed ID: 7907854
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer.
Tsutsui S; Kataoka A; Ohno S; Murakami S; Kinoshita J; Hachitanda Y
Clin Cancer Res; 2002 Nov; 8(11):3454-60. PubMed ID: 12429634
[TBL] [Abstract][Full Text] [Related]
38. Gastric carcinoma: expression of c-erbB-2/neu oncoprotein, epidermal growth factor receptor, cathepsin D, progesterone receptor and tumor associated glycoprotein-72 in different histological types.
Peláez Buján Mdel C; Ruibal Morell A; Aza González J
Rev Esp Enferm Dig; 1999 Dec; 91(12):826-37. PubMed ID: 10619912
[TBL] [Abstract][Full Text] [Related]
39. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
40. Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis.
Slesak B; Harlozinska A; Porebska I; Bojarowski T; Lapinska J; Rzeszutko M; Wojnar A
Anticancer Res; 1998; 18(4A):2727-32. PubMed ID: 9703936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
